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Does aberrant membrane transport
contribute to poor outcome in adult
acute myeloid leukemia?
Alexandre Chigaev*
Department of Pathology and Cancer Center, University of New Mexico Health Sciences Center, University of New Mexico,
Albuquerque, NM, USA
Acute myeloid leukemia in adults is a highly heterogeneous disease. Gene expression
profiling performed using unsupervised algorithms can be used to distinguish specific
groups of patients within a large patient cohort. The identified gene expression
signatures can offer insights into underlying physiological mechanisms of disease
pathogenesis. Here, the analysis of several related gene expression clusters associated
with poor outcome, worst overall survival and highest rates of resistant disease and
obtained from the patients at the time of diagnosis or from previously untreated
individuals is presented. Surprisingly, these gene clusters appear to be enriched for
genes corresponding to proteins involved in transport across membranes (transporters,
carriers and channels). Several ideas describing the possible relationship of membrane
transport activity and leukemic cell biology, including the “Warburg effect,” the specific
role of chloride ion transport, direct “import” of metabolic energy through uptake of
creatine phosphate, and modification of the bone marrow niche microenvironment are
discussed.
Keywords: adult acute myeloid leukemia, poor outcome, gene expression signature, membrane transport,
transporters, channels, poor prognosis, prognostic indicators
Introduction
In adults and older patients acute myeloid leukemia (AML), the most common type of adult
leukemia in USA, is often present as highly resistant disease (RD) with very poor outcomes
(Lang et al., 2005). AML is a highly heterogeneous disease, and with the exception of a relatively
well deﬁned acute promyelocytic leukemia (APL) characterized by t(15;17)(q22;q21) PML-RARA
fusion, it exhibits a highly diverse clinical course and requires diﬀerent treatment modalities
(Liersch et al., 2014). Consequently, for an informed therapeutic decision a large number of
prognostic factors including but not limited to age, white blood cell (WBC) count, the presence of
recurring cytogenetic abnormalities, and individual gene mutations needs to be assessed (Liersch
et al., 2014). However, a large number of AML cases have risk-indeterminate or normal karyotypes
(Cagnetta et al., 2014), and a fewer number of mutations has been identiﬁed inmost AML genomes
than in most other adult cancers (The Cancer Genome Atlas Research Network, 2013; Grove
and Vassiliou, 2014). Moreover, epigenetic deregulation can be also a signiﬁcant part of AML
pathogenesis (Larsson et al., 2013). Thus, prognostication of outcomes and residual disease, as well
as of clinical course or relapse rates (RRs) poses signiﬁcant challenges.
Developed in the last decade, global gene expression analysis is now envisioned as an
independent prognostic marker that can be used to classify patients into pathologic groups,
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signiﬁcantly improving cytogenetic-based classiﬁcation schemes.
As a result, this approach led to the identiﬁcation of a
web of deregulated genes, non-coding RNAs, and epigenetic
modiﬁcations speciﬁcally important for patients with normal
cytogenetic evaluations (Cagnetta et al., 2014). However, gene
expression proﬁling can also identify intrinsic biological groups
of AML within a well-characterized patient cohort, and thus,
have the ability to oﬀer insights into physiological mechanisms
of leukemia pathogenesis (Wilson et al., 2006), provided that
unsupervised approaches unrelated to other external factors such
as survival, clinical signs, karyotypic abnormalities or individual
gene mutations are used. Despite the fact that gene expression
is typically assessed on the level of mRNA (cDNA or cRNA), it
is usually assumed that up-regulated mRNA levels are related to
protein expression, and this will lead to a somewhat enhanced
protein-speciﬁc function.
Here, the analysis of several related gene expression clusters
[Cluster B in referenc Wilson et al. (2006) and Clusters 7 and
8 in reference Valk et al. (2004)] identiﬁed using unsupervised
algorithms and originating from pretreatment patient samples
with primary AML (Valk et al., 2004), or previously untreated
de novo or secondary AML (Wilson et al., 2006) is presented.
These clusters appear to be enriched for genes corresponding
to proteins involved into transport across cell membranes
(transporters, carriers, and channels). Because these clusters are
associated with poor outcome, a speciﬁc role for membrane
transport in adult AML is postulated. Several hypotheses
describing a relationship of membrane transport activity and
leukemic cell biology are discussed.
Cluster Analysis and Unsupervised
Algorithms
Gene expression signatures are generated using gene-based
clustering, which identiﬁes sets of genes that have high
probability of being co-expressed (Do and Choi, 2008).
Numerous clustering algorithms have been developed, and
several excellent reviews that describe clustering approaches have
been recently published (Nugent and Meila, 2010; Wang et al.,
2013). However, for the purpose of this report it is necessary
to describe the two major classes of clustering methodology:
supervised and unsupervised (Do and Choi, 2008).
Supervised methods take into account known in advance
phenotypic parameters of the analyzed samples, or other
descriptors that characterize groups of samples. As a result, the
subsets of genes whose level of expression exhibit correlation with
the speciﬁed class descriptors are identiﬁed. The weakness of this
method is that it leads to the identiﬁcation of small gene subsets,
often identiﬁed as “informative genes,” and other unrelated genes
are perceived as noise (Do and Choi, 2008). Therefore, clustering
algorithms that employ supervised methods are only as good
as the predeﬁned set of class descriptors. For heterogeneous
diseases, such as AML, a set of informative genes can be largely
dependent on the heterogeneity of the initial data.
For unsupervised approaches the analysis is based on the
assumption that the variability of a group of variables depends
upon a certain factor (principal component) that is hidden
from the observer. This type of analysis can lead to the
identiﬁcation of an underlying pattern in the data, and provide
additional clues into a process or biological meaning. This
type of analysis is vital when the overall goal is to uncover
a previously undeﬁned relationship or to formulate a new
hypothesis. However, if a pattern is absent, the results would have
no meaning.
Patients with Worst Overall Survival (OS)
and Highest Rates of Resistant Disease
One of the requirements for the analysis of a cohort of
patients is the ability to analyze previously untreated de novo
or secondary AML. The power of a retrospective analysis is that
gene expression proﬁles can be directly correlated to the disease
outcomes. It is understandable why a speciﬁc focus has been on
clusters of genes that correlated with the worst disease-free and
overall patient survival (DFS and OS), and high rates of RD.
Therefore, cluster B from the report (Wilson et al., 2006), which
coincided with the poorest clinical outcomes, an exceptionally
high rate (77%) of RD and the lowest DFS, attracted immediate
attention. Moreover, the number of signiﬁcant cluster-deﬁning
genes from cluster B from this study was similar to the gene
signature from clusters 7 and 8 from (Valk et al., 2004). The
majority of the top 50 ranked genes from cluster B (∼90%)
represented up-regulated genes, whereas a signiﬁcant portion of
top ranked genes in other clusters were down-regulated (Wilson
et al., 2006). Unfortunately, no survival data for clusters 7 and 8
were provided in (Valk et al., 2004).
According to Wilson et al. (2006) cluster B represented an
“interesting group of 22 patients,” where the majority (77%) was
unresponsive to the induction therapy, and three patients with
achieved remission relapsed within the ﬁrst 16 months. Also,
42% of all cases in cluster B showed normal karyotype, one
patient had both NPM1 and FLT3 internal tandem duplication
(ITD) mutations and two individuals had FLT3-ITD (Wilson
et al., 2006). In Valk et al. (2004) clusters 7 and 8, where gene
signatures were similar to cluster B, the number of cases showing
normal karyotype were 67 and 31% respectively, with 22% of
cases exhibiting FLT3-ITD and 11% with EVII overexpression in
cluster 7 and 8% of N-Ras in cluster 8. Thus, a signiﬁcant fraction
of cases had no recurring cytogenetic abnormalities previously
described individual gene mutations.
Unsupervised Gene Clusters from Two
Independent Studies are Enriched for
Genes Corresponding to Proteins
Involved in Membrane Transport
Previously, Wilson et al. (2006) reported that Clusters 7 and 8
of Valk et al. (2004) had a gene expression proﬁle most similar
to cluster B. It has been noted that one of genes overexpressed
by these patients was ABCG2, a member of ATP-binding cassette
(ABC) superfamily of membrane transporters, also termed breast
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cancer resistance protein (BCRP1), later dubbed as a stem cell
marker and a target in cancer stem cell therapy (Ding et al., 2010).
Moreover, ABCG2 protein overexpression in concurrence with
FLT3-ITD mutation identiﬁes a subgroup of AML patients with
signiﬁcantly worse prognosis (Tiribelli et al., 2011).
Our analysis of the top most signiﬁcant discriminating genes
from all three clusters revealed an unanticipated phenomenon:
these clusters were enriched in genes functionally involved in
membrane transport – transporters and channels (Table 1). Here
protein functions are described according to UniprotKB1 and
Gene Ontology2 databases. For gene function annotation from
UniprotKB, reviewed (curator-evaluated) computational records
(Swiss-Prot) were used. Below, a review of the speciﬁc gene
functional roles is presented. This review is only intended to show
data that are relevant for this particular context. For multiple
genes listed below exhaustive literature reviews do exist.
ABCG2/BCRP1
ABCG2 ﬁrst attracted wide attention from the scientiﬁc
community when it was described as an ABC transporter
expressed in a variety of stem cells and as a speciﬁc pump
responsible for acquisition of a ‘side-population’ (SP) phenotype
(Zhou et al., 2001). The AML SP contains leukemic stem cells
(LSCs), and it can be detected in bone marrow and peripheral
blood samples at diagnosis (Moshaver et al., 2008).
In earlier reports, as for other multidrug resistance (MDR)
transporter proteins, ABCG2 had been implicated in the
development of drug resistance (Benderra et al., 2004; Galimberti
et al., 2004). However, more recent studies suggest that ABCG2
and MDR1 transporter-proteins have a limited role in drug
resistance in vivo and in vitro (Svirnovski et al., 2009).
Nonetheless, high expression of ABCG2 mRNA is shown
to be an independent prognostic factor for RR and DFS
in adult AML. A correlation between the expression of the
three major ABC pumps (ABCB1, ABCC1, and ABCG2) and
FLT3-ITD and MLL-PTD (partial tandem duplication) in AML
patient samples were also reported (Nasilowska-Adamska et al.,
2014). Also, in adult de novo AML with normal karyotype,
ABCG2-positive cases presented an increased risk of relapse, and
ABCG2 overexpression inversely correlated with the duration of
complete remissions (Damiani et al., 2006). Thus, the presence of
up-regulated ABCG2 mRNA in the gene clusters that correlate
with poor clinical outcome is well supported by other data.
However, the upregulated message is not likely related to the drug
resistance and clonal selection of cells overexpressing the pump,
since tumor samples were obtained at the time of diagnosis (Valk
et al., 2004), or from previously untreated individuals (Wilson
et al., 2006).
ATP1B2, Sodium/Potassium-Transporting
ATPase Subunit Beta-2, AMOG
ATP1B2 is the non-catalytic component of the
sodium/potassium-transporting ATPase (Na(+)-K(+)-ATPase),
1http://www.uniprot.org/uniprot/
2http://www.ebi.ac.uk/QuickGO/
which catalyzes the hydrolysis of ATP coupled with the exchange
of Na+ and K+ ions across the plasma membrane. The function
of the beta-2 subunit is unclear, however, the beta-1 subunit
could be important for targeting of the Na(+)-K(+)-ATPase to
caveolae (Liu and Askari, 2006). Another function of ATP1B2 is
in mediating cell adhesion on glia (AMOG), where it is highly
expressed on the cell surface. AMOG is a heavily glycosylated
protein that participates in cell adhesion in the CNS (Gloor
et al., 1990). In glioblastoma-derived cells, expression of
ATP1B2 down-modulates brain tumor-initiating cell invasion
without signiﬁcantly aﬀecting cell proliferation (Sun et al.,
2013).
In an eﬀort to identify epigenetically silenced tumor
suppressor genes (TSGs) in mouse mammary tumors, Demircan
et al. (2009) cultured tumor cells with a demethylating drug.
One of the TSGs identiﬁed was Atp1B2. In a panel of
human breast tumors, authors observed that human ortholog
ATP1B2 was aberrantly hypermethylated (Demircan et al.,
2009). Epigenetic regulation of ATP1B2 expression was also
reported in malignant gliomas (van den et al., 2006). The role
of ATP1B2 in the pathogenesis of leukemia has yet to be
investigated.
CLCN3, H(+)/Cl(−) Exchange Transporter
3, ClC-3
ClC-3 belongs to the family of voltage-sensitive chloride
channels3. ClC-3 is an antiporter that mediates exchange of
protons against chloride ions, and participates in the acidiﬁcation
of endosomal compartments. It is expressed in tumors of diﬀerent
origin and reported to be speciﬁcally upregulated in glioma
cells (Olsen et al., 2003). ClC-3 plays an important role in
the regulation of cell cycle and cell migration, and speciﬁcally
participates in the regulation of osmotic gradients and cell
volume during cell-cycle progression (Habela et al., 2008; Mao
et al., 2009; Cuddapah et al., 2012).
ClC-3 can be detected in late endosomal/lysosomal
compartments, and through increased acidiﬁcation of vesicles it
increases cell resistance to the chemotherapeutic drug etoposide.
This was achieved in the absence of a detectable expression of
MDR transporters (Weylandt et al., 2007).
Also, ClC-3 is implicated in regulating apoptosis. In
nasopharyngeal carcinoma cells, speciﬁc chloride channel
blockers inhibited paclitaxel-induced apoptosis. At the same
time, ClC-3-si-RNA knockdown experiments and other
evidence suggests that ClC-3 represents a critical target for
chemotherapeutic drug paclitaxel (Zhang et al., 2013). High
expression of ClC-3 is reported to be a predictor of poor survival
in lung adenocarcinoma, breast adenocarcinoma, and liver
cancer, and this can be associated with the eﬀect of the protein
on tumor metastasis (Xu et al., 2014). A recently published
review speciﬁcally addresses involvement of ClC-3 in cancer and
explores its potential for therapy (Hong et al., 2015).
3http://www.genenames.org/genefamilies/CLCNS#CLCN
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CLIC2, Chloride Intracellular Channel
Protein 2 (XAP121)
CLIC2 belongs to the family of chloride intracellular channel
(CLIC) proteins4 that are implicated in membrane transport, cell
division, secretion, and apoptosis (Ashley, 2003). These proteins
possess an unusual feature: they can exist in a water soluble state
and can insert into the membrane to form an anion channel
(Ashley, 2003; Cromer et al., 2007; Jiang et al., 2014). CLIC2
is shown to interact with ryanodine receptor (RyR1), and to
modulate calcium release from intracellular stores (Board et al.,
2004; Meng et al., 2009). Some of the intracellular chloride
channels from CLIC and other families are envisioned as proteins
that “may contribute to a cancer phenotype” (Suh and Yuspa,
2005), however, no signiﬁcant role for CLIC2 has been previously
reported. Nonetheless, two related CLICs, CLIC1 and CLIC4,
are overexpressed in cancer stem cells and envisioned as novel
therapeutic targets (Peretti et al., 2014). Also, CLIC-like chloride
channels are localized at the osteoclast ruﬄed border, and
together with H+-ATPase, they participate in the acidiﬁcation
of the bone resorption compartment (Schlesinger et al., 1997;
Supanchart and Kornak, 2008). Thus, CLIC2 represents a
part of the plasma membrane machinery that actively triggers
dissolution of the bone mineral matrix by lowering extracellular
pH (Arnett, 2008), and leads to the dramatic changes in the niche
microenvironment ionic composition.
Solute Carrier (SLC) Proteins
Solute carrier is a large group of proteins that includes more than
four dozen protein families and 395 transporter genes in human
genome (Hediger et al., 2013)5. Both Cluster B in reference
Wilson et al. (2006) and Clusters 7 and 8 in reference Valk
et al. (2004) contained several members of this group (Table 1):
SLC42 [Rhesus (Rh) glycoproteins, ammonium transporter
family], SLC2A1 (glucose and/or fructose transporter GLUT1),
SLC4A1 [bicarbonate transporter family anion exchanger (AE),
member 1 (Diego blood group)], SLC6A8 (Sodium- and chloride-
dependent creatine transporter 1), and SLC6A9 [sodium- and
chloride-dependent glycine transporter 1 (GlyT1)]. In April–June
2013 Molecular Aspects of Medicine published a special issue
(Volume 34, Issues 2–3, Pages 95–752) speciﬁcally dedicated to
SLC transporters. This series of papers represents an excellent
collection of in-depth reviews. Here, a summary of the most
signiﬁcant observations relevant in this context is presented.
Rhesus Glycoproteins, SLC42
Transporters, RHAG, RHCE, RHD
Historically Rh glycoproteins were studied in human blood
because of their immunogenicity and importance for gestation.
The relationship between Rh protein expression and NH3/NH4+
4http://www.genenames.org/genefamilies/CLCNS#CLIC
5http://www.genenames.org/genefamilies/SLC
was established in the late 1990s- early 2000s (Nakhoul and
Lee, 2013). However, details which include stoichiometry,
electrogenicity, and the exact nature of translocated substances
are still unclear.
RhAG studies suggest that an electro-neutral transport of
NH4+ is coupled with an antiport of a proton resulting in a
net transport of NH3 (Westhoﬀ et al., 2002). Other evidence
suggests that RhAG directly participates in the transport of
NH4+ and NH3 (Benjelloun et al., 2005). Transport of CO2 in a
gaseous form or as HCO3− is also plausible. It was also suggested
that substrate speciﬁcity can be modulated by pH and other
factors (Nakhoul and Lee, 2013). Thus, Rh proteins can play a
signiﬁcant role in the maintenance of acid-base balance as well
as transport of NH3/methylamine/NH4(+)/CO2 (Van Kim et al.,
2006; Nakhoul and Lee, 2013; Weiner and Verlander, 2014). No
direct relationship to cancer or cancer cell metabolism has been
previously reported. Diseases associated with Rh protein function
include red blood cell-related disorders such as hemolytic disease
of the newborn, auto-immune hemolytic anemia and others
(Huang et al., 2000; Van Kim et al., 2006). Rh proteins are also
related to chronic metabolic acidosis, impaired urinary NH4+
excretion in response to acid loads and other disorders where
transport of ammonia and/or regulation of acid-base balance are
critical (Seshadri et al., 2006; Biver et al., 2008). Rh protein family
is also envisioned as a class of “ammonium sensor” proteins
that may modulate diverse cellular functions in response to the
changes in extracellular ammonium content (Van Kim et al.,
2006).
SLC2A1, GLUT1, Glucose Transporter
Type 1
The protein encoded by human GLUT1 belongs to the sugar
porter subfamily of the major facilitator superfamily (Henderson
and Baldwin, 2013). It facilitates glucose diﬀusion, and is
responsible for basal uptake of glucose. It also exhibits broad
substrate speciﬁcity and is reported to transport a range of aldoses
including both pentoses and hexoses (Thorens and Mueckler,
2010). GLUT1 is often overexpressed in a variety of tumors,
suggesting that GLUT 1 is required for elevated glucose uptake
in cancer (Amann and Hellerbrand, 2009; Ramani et al., 2013;
Kaira et al., 2014), which can result from a speciﬁc metabolic
phenomenon, aerobic glycolysis often described as the “Warburg
eﬀect”(Warburg, 1956b; Diaz-Ruiz et al., 2011).
In BCR-Abl+ B-cell acute lymphoblastic leukemia genetic
deletion of Glut1 was suﬃcient to decrease glucose uptake and
modify metabolic ﬂux of glucose toward catabolism. In vivoGlut1
deletion resulted in suppression of disease progression. Authors
concluded that B-cells mainly rely on Glut1 transport to maintain
its metabolism, even in the presence of other glucose transporters
(Liu et al., 2014). In AML patient samples high expression of
GLUT1 was correlated with poor chemotherapy responsiveness.
Authors concluded that GLUT1 could be a potential target
to drug resistance reversal (Song et al., 2014). Also, GLUT1
represents one of the HIF-1α target genes (Majumder et al., 2004)
that can be down-regulated by inhibitors of the mTOR signaling
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pathway in AML cells (Zeng et al., 2007), or speciﬁc HIF-1
inhibitors in B-cell CLL/lymphoma-2 (BCL2; Yonekura et al.,
2013). Thus, an occurrence of up-regulated GLUT1 expression
in the gene clusters that correlate with poor clinical outcome
is not surprising given its well reported role in cancer in other
studies.
SLC4A1, Anion Exchanger, Member 1,
Chloride-Bicarbonate Exchanger
SLC4A1, anion exchanger-1 (AE1), mediates the electroneutral
Cl(−)/HCO(−)3 exchange across the plasma membrane,
sulfate uptake, or proton and sulfate symport. It has been
also suggested that the transport site of AE1 can also
mediate the cation leak (Barneaud-Rocca et al., 2011). Other
functions include association with the cytoskeleton through
interaction with ankyrin and the actin/spectrin cytoskeleton,
maintaining cell integrity and acid–base homeostasis and
regulation of glycolysis (Walsh and Stewart, 2010; Wu et al.,
2011).
In early 2000, it was noted that co-expression of AE1
cDNA together with Rh glycoprotein polypeptides (RHCE
or RHD) increased the binding level of antibody speciﬁc to
the endogenous Rh glycoproteins (Beckmann et al., 1998).
Next, a macrocomplex consisting of AE1 and Rh proteins
(Rh-associated glycoprotein, Rh polypeptides, glycophorin
B, CD47 and LW) was described. Authors proposed that
the macrocomplex represents an integrated CO2/O2/NO gas
exchange unit (metabolon), where Rh proteins may act as
“gas channels” that are located in close proximity to AE1
proteins providing H+ and HCO(−)3 movements necessary
for eﬃcient O2/CO2 exchange (Bruce et al., 2003). The model
of the band 3 (AE1) macrocomplex has been modiﬁed to
include glycolytic enzymes: aldolase, phosphofructokinase,
and glyceraldehyde-3-phosphate dehydrogenase, and this
association reduces enzymatic activity. An intricate model of
AE1 macrcomplex regulation has been proposed (De Rosa et al.,
2008).
No speciﬁc role for AE1 in hematological malignancies
can be found. A series of reports describes the role of AE1
in gastric cancer. Expression of AE1 and cyclin-dependent
kinase inhibitor tumor suppressor p16 has been studied in
samples from patients with early and advanced stages of gastric
cancer. The nuclear vs. cytoplasmic localization of p16 was
dependent on the disease stage, with increased cytoplasmic
localization in advanced cancer cells. P16 cytoplasmic expression
correlated with AE1 expression, and both were associated with
an absence of metastasis (Liu et al., 2009). Silencing of AE1
decreased cell proliferation. In a xenograft model experimental
hypergastrinemia resulted in the down-regulation of AE1 and
p16 expression and promoted growth inhibition (Tian et al.,
2010). Another report revealed that AE1 expression in gastric
carcinoma tumor samples strongly correlated with the onset and
progression of cancer (Xu et al., 2009). In two mouse models of
gastric cancer, the targeting of AE1 using siRNA resulted in down
regulation of AE1 in gastric mucosa, decreased tumor growth,
and lowered the rate of tumor detection. Authors concluded that
AE1 silencing could provide a novel approach to treatment of
gastric cancer (Suo et al., 2012).
An interesting study describes regulation of AE1 expression
by the microRNA, miR-24 (Wu et al., 2010), which is critical
for the development of normal hematopoietic progenitors, is
highly expressed in primary AML, regulates hematopoietic
cell survival (Nguyen et al., 2013), and is down-regulated
during erythroid diﬀerentiation (Georgantas et al., 2007). AE1
protein demonstrates opposite dynamics of expression during
diﬀerentiation. It is expressed only in a small fraction of
early erythroid progenitors and it is up-regulated during
erythroid diﬀerentiation (see Lehnert and Lodish, 1988) and
(Table II in McAdams et al., 1998). Thus, this relationship
suggests that miR-24 down regulation provides a regulatory
mechanism for AE1 expression during diﬀerentiation (Wu et al.,
2010).
In AML patient samples miR-24 expression has had no
correlation with the mutations of genes FLT3-ITD, NPM1,
C-KIT, IDH1/IDH2, DNMT3A, N/K-Ras and C/EBPA. However,
miR-24 high expression was frequently detected in patients
with t(8;21), with no signiﬁcant correlation with OS or
relapse-free survival (RFS; Yin et al., 2014). Since t(8;21)
is often detected in patients with (French–American–British
Classiﬁcation) FAB AML-M2 subtype and represents one of the
favorable abnormalities with one of highest complete remission
rates after conventional chemotherapy (Nishii et al., 2003),
(Reikvam et al., 2011), it is unlikely that Clusters 7 and 8 in
reference Valk et al. (2004) and Cluster B in reference Wilson
et al. (2006), which showed the worst DFS and OS possess high
miR-24 expression. Though, no t(8;21) were detected in Cluster
B (see Table 3 in Wilson et al., 2006), and in reference Valk
et al. (2004), the AML1-ETO fusion gene was grouped within
cluster 13.
Solute Carrier (SLC6) Protein Family
Among genes up-regulated in poor outcome gene clusters, two
belong to the family of SLC6 Na+/Cl− dependent secondary
active co-transporters (SLC6A8 and SLC6A9). The major
functional role of SLC6 transporters is to mediate rapid
uptake of small amino acid or amino acid-like substrates,
neurotransmitters, amino acids, osmolytes and creatine, against
very large concentration gradients (Pramod et al., 2013). SLC6
transporters exhibit diﬀerent ion coupling stoichiometry, 1-3
Na+; 1-2 Cl−, to 1 substate molecule, or for some SLC6members,
a non-stoichiometric transport, as well as a Na+ leak current
can be observed in the absence of substrate (Kristensen et al.,
2011). Numerous, disease associations of SLC6 family members
have been reported. Speciﬁcally, these are creatine deﬁciency
syndrome, mental retardation, musculoskeletal disorders for
SLC6A8, and schizophrenia and hypertension for SLC6A9
(Longo et al., 2011; Pramod et al., 2013). A speciﬁc role of
SLC6A8 in the “import” of metabolic energy in colon cancer cells
has been also described (Loo et al., 2015; Sullivan and Christofk,
2015).
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SLC6A8, Sodium- and
Chloride-Dependent Creatine
Transporter 1 (CT1; Creatine
Transporter 1)
SLC6A8, creatine transporter 1 is one of the major creatine
transporters in humans. It is associated with the plasma
membrane and mediates an uptake of creatine in symport with
sodium and chloride ions and, presumably, it provides creatine
in cells where it cannot be synthesized (Nash et al., 1994; Sora
et al., 1994; Pramod et al., 2013).
Creatine phosphate is one of the compounds that possess a
high phosphoryl potential and therefore, it is required for the
utilization of ATP-derived energy. Large levels of creatine are
present in muscle, brain and heart, where rapid high energy
production is essential for the physiology of the organ or tissue
(Wyss and Kaddurah-Daouk, 2000; Longo et al., 2011). The fact
that CT1mRNA is up-regulated in gene clusters of poor-outcome
AML hints at the possibility that these cells possess a high energy
phenotype.
A recent report highlighted the role of SLC6A8 and creatine
phosphate in the metastatic survival and colonization of colon
cancer (Loo et al., 2015; Sullivan and Christofk, 2015). After
a screen of 661 human miRNAs for their ability to suppress
colonization of the liver by colon cancer cells, authors identiﬁed
miR-551 and miR-483 as suppressors of colon cancer metastasis.
Both miRNAs target brain-type creatine kinase (CKB) that is
released by metastatic cells into the extracellular space where it
catalyzes the formation of creatine phosphate from extracellular
creatine and ATP. Next, creatine phosphate is taken up by
cancer cells through SLC6A8 and is used to generate ATP and
support survival of metastatic cells. Therapeutic viral delivery
of two miRNAs decreased colon cancer metastasis. miRNA
treatment signiﬁcantly reduced expression of both (CKB and
SLC6A8) proteins that were shown to be expressed at higher
levels on metastatic cells as compared to primary tumors (Loo
et al., 2015). Thus, SLC6A8 represents an essential part of
a unique mechanism where creatine phosphate, a compound
containing a high energy phosphate bond (∼P), is directly
delivered into cancer cell, providing a substrate for transfer of
its phosphoryl group to ADP and the generation ATP. Thus, the
metabolic energy that is normally generated through intracellular
processes that include glycolysis and oxidative phosphorylation
can be directly “imported” into the cancer cell. Since SLC6A8
is up-regulated in samples obtained from poor-outcome AML
patients, it is tempting to postulate the existence of a similar
mechanism.
SLC6A9, Sodium- and
Chloride-Dependent Glycine
Transporter 1 (GlyT-1)
SLC6A9, (glycine transporter 1) mediates rapid uptake of the
amino acid glycine (Gly) in symport with sodium and chloride
ions. Reported stoichiometry is 2 or 3 Na+ and 1 Cl−, per 1 Gly
(Kristensen et al., 2011). It is responsible for rapid removal of
the amino acid neurotransmitter Gly from the synaptic cleft and
the termination of the neurotransmission signal (Lopez-Corcuera
et al., 2001). In CNS GlyT1 is expressed on glial cells, as well
as on neurons. It is localized on astrocytes and on pre-synaptic
and post-synaptic membranes of glutamatergic synapses. GlyT1
transporter is reported to physically associate with the N-methyl-
D-aspartate (NMDA) receptor (Raiteri and Raiteri, 2010).
SLC6A9 disease associations include schizophrenia (Tsai et al.,
2006a,b; Deng et al., 2008), and hypertension (Ueno et al., 2009).
GlyT gene deletion studies supported other data that indicate
therapeutic potential of GlyT1 inhibitors for the treatment
of psychiatric and neurological disorders (Aragon and Lopez-
Corcuera, 2005). In cancer, GlyT1 transporters are implicated
in regulation of pain, and GlyT inhibitors are envisioned as a
novel class of drugs for neuropathic pain management (Dohi
et al., 2009). For example, a recent report showed that oral or
IV administration of GlyT1 inhibitor drastically improved pain-
like behavior in a mouse femur bone cancer model. Authors
concluded that GlyT inhibitors can provide a new path toward
the treatment of bone cancer pain with morphine or alone
(Motoyama et al., 2014). No speciﬁc role for GlyT1 has been
previously reported for hematological malignancies.
Selenium-Binding Protein 1 (56 kDa
Selenium-Binding Protein), SBP56, SP56,
SBP1
Because SBP1 protein can bind selenium, it has been suggested
that SBP1 is implicated in the transport of the element (Chang
et al., 1997). However, the exact SBP1 function remains unclear.
Nevertheless, since it has been suggested that SBP1 protein may
participate in intra-Golgi transport (Porat et al., 2000), it was
included into this study.
During the last decade, numerous studies reported
associations between SBP1 and cancer. In tumors of epithelial
origin SBP1 is highly expressed in diﬀerentiated cells. A decrease
in the expression of SBP1 detected at the level of mRNA or
protein correlates with shorter DFS and OS in patient with
colorectal tumors (Li et al., 2008). Expression of SBP1 was
suppressed in gastric carcinoma; however, it was still high in
precursor lesions. Reduced SBP1 expression was also associated
with poor survival (Zhang et al., 2011a,b). In esophageal
adenocarcinoma expression of SBP1 decreased signiﬁcantly
with disease progression. An overexpression of SBP1 elevated
cisplatin sensitivity and promoted apoptosis in the presence of
methylselenic acid. Thus, expression of SBP1 is envisioned as a
predictor of the response to chemosensitization (Silvers et al.,
2010).
Several studies point toward the role of epigenetic regulation
of SBP1 expression. It was reported that SBP1 levels in colon
cancer tissues are related to hypermethylation of the SBP1
promoter, and treatment with an epigenetic modiﬁer that inhibits
DNA methyltransferase activity resulted in the up-regulation of
SBP1 mRNA and protein (Pohl et al., 2009). Epigenetic changes
that included promoter hypermethylation were also reported
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in esophageal adenocarcinoma. Diﬀerential splicing and single
nucleotide polymorphism also contributed to the regulation
of SBP1 protein levels (Silvers et al., 2010). A recent review
describes a speciﬁc role of SBP1 as a prognostic factor and tumor
suppressor (Yang and Diamond, 2013).
Thus, it is not surprising that the SBP1 gene was detected
in the gene cluster corresponding to the group of patients with
poor-outcome adult AML. However, the fact that SBP1 was
signiﬁcantly up-regulated in both clusters [see positive sorting
and assembly machinery (SAM) scores in supplemental data for
(Valk et al., 2004)] poses a question about a physiological role
of this protein in hematopoietic cells. No data about SBP1 in
leukemia can be found.
Mitochondrial Import Receptor Subunit
TOM7, Translocase of Outer Membrane
7 kDa Subunit Homolog
TOM7 protein is an integral part of the translocase of the
outer mitochondrial membrane (TOM complex) that provides an
entry point for ∼99% of all precursor proteins in mitochondria.
Since only 13 out of ∼1500 proteins in the mitochondrial
proteome are encoded by the mitochondrial genome, the TOM
complex represents an essential part for proper functioning of
the organelle (Harbauer et al., 2014; Opalinska and Meisinger,
2014). The general import pore, where proteins are transported
across the outer membrane (TOM), consists of multiple proteins
designated: TOM22 and TOM40 stably associated central
proteins, TOM20 and TOM70 protein precursor receptors, and
the three small TOM proteins: TOM5, TOM6, and TOM7
(Rehling et al., 2001).
Earlier studies suggested that TOM7 may play a regulatory
role in the assembly of the TOM complex. The deletion of
TOM7 resulted in the stabilization of the complex, induced better
association between TOM40 and TOM22, and reduced import of
porin, also known as voltage-dependent anion-selective channel
protein, one of the most abundant proteins in the mitochondrial
outer membrane (Honlinger et al., 1996). The analysis of multiple
single and double mutants of the three small Tom proteins in
Neurospora crassa revealed that only mutants lacking both Tom6
and Tom7 proteins showed signiﬁcantly altered phenotype.
Single mutants lacking Tom7 or Tom6 exhibited drastically
diﬀerent abilities to import diﬀerent proteins. Authors proposed
that Tom7 andTom 6 play diverse roles in the targeting/sorting of
imported proteins into mitochondrial compartments (Sherman
et al., 2005). However, as noted by Harbauer et al. (2014), it is
important to remember that regulatory processes described in
lower eukaryotes may diﬀer between diﬀerent organisms and cell
types.
TOM7 is also implicated in the regulation of the SAM
(complex) that participates in the transport of beta-barrel
precursor proteins (Meisinger et al., 2006; Wideman et al.,
2010). Tom7 was reported to disrupt the formation of the
complete SAM and to promote segregation of the mitochondrial
distribution and morphology protein Mdm10. Deletion of Tom7
stimulated formation of the complex between SAM and Mdm10.
Authors concluded that Tom7 plays an important role in sorting
and segregation of mitochondria outer membrane components
(Meisinger et al., 2006). Also, Tom7mediatesMdm10-dependent
assembly of Tom40 complex by regulating its release from the
SAM complex (Yamano et al., 2010).
Moreover, Tom7 plays an essential role in the biogenesis
of mitochondria though modulation of two proteins: Tom40
and Tom22. At the early stage, it inhibits Tom40 complex
formation by antagonizing Tom5 and Tom6. At the later stage,
it induces the dissociation of the SAM-Mdm10 complex by
sequestering unbound Mdm10, and thus delays the formation of
Tom22:Tom40 complex (Becker et al., 2011). Therefore, Tom7
is one of the critical regulatory components responsible for the
assembly and regulation of TOM and SAM complexes.
No direct association between cancer and TOM7 has been
reported. However, numerous mitochondrial dysfunctions are
associated with a large number of pathologies including cancer.
Certain mitochondrial enzymes can act as tumor suppressors.
Defects in isocitrate dehydrogenase, succinate dehydrogenase,
and fumarate hydratase are implicated in gliomas (Nunnari
and Suomalainen, 2012). Metabolic reprogramming, essential
for rapid cell proliferation, requires synthesis of large quantities
of amino acids, nucleotides and lipids and is directly related
to aerobic glycolysis, also called the Warburg eﬀect (Warburg,
1956a,b). Moreover, multiple components of mitochondrial
import machinery are reported to be up-regulated in cancer
and in some cases can be associated with poor prognosis.
Certain components of the mitochondrial intermembrane space
assembly complex were implicated in metabolic reprogramming
during carcinogenesis (see Opalinska and Meisinger, 2014, and
references therein). Thus, it was not surprising that one of the
regulatory subunits of the TOM complex (TOM7) was found to
be up-regulated in poor-outcome AML. The exact role of TOM7
in leukemogenesis requires further investigation.
Membrane Transport Protein XK, Kell
Complex 37 kDa Component, X-Linked
Kx Blood Group
The protein encoded by XK X-linked Kx blood group gene
possesses structural characteristics of membrane transport
proteins. XK is considered a putative transporter of unknown
function. However, based on protein similarity and experimental
data it has been proposed that XK could be involved in sodium-
dependent transport of neutral amino acids or oligopeptides or
regulation of cation transport (Ho et al., 1994; Carbonnet et al.,
1998; Rivera et al., 2013; also see Uniprot link in Table 1).
XK protein is expressed in a number of tissues including
CNS and blood cells (Russo et al., 2000; Claperon et al.,
2007), and mutations within XK protein are associated with
McLeod syndrome, which is characterized as a multisystem
disorder with numerous abnormalities in the neuromuscular and
hematopoietic systems (Ho et al., 1994; Arnaud et al., 2009;
Dubielecka et al., 2011; Zhu et al., 2014). In erythrocytes XK
protein is associated with Kell protein, a zinc endopeptidase
with endothelin-3-converting enzyme activity. It is proposed
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that the Kell/XK complex operate as a regulator of erythrocyte
volume (Rivera et al., 2013). Kell is expressed on a broad range
of haematopoietic cells including myeloid progenitors (Wagner
et al., 2000). However, no known association with leukemia or
other cancers has been reported in the literature.
Thus, the RNA message for multiple proteins involved in the
membrane transport was reported to be up-regulated in samples
obtained from adult AML patients with poor outcome. The data
are graphically summarized in Figure 1.
Transporter Up-Regulation, What Does It
Mean?
At ﬁrst glance, based on the nature of channel/transporter
substrates, this group of proteins can be divided into
two: transporters involved in transport of nitrogen
containing compounds and products of nitrogen metabolism
(ABCG2, SLC6A9, SLC6A8, SLC42A1, RHCE, RHD), and
channels/transporters involved in regulation of acid-base balance
and inorganic ion transport (CLIC2, ATP1B2, CLCN3, SLC4A1,
SLA42 proteins, XK). Glucose transporter GLUT1, BP1 and
TOM7 are not directly related to either group. Analysis of
the existing literature suggested four major ideas regarding a
potential relationship between overexpressed genes encoding
transport proteins and possible physiological features of these
samples. These lines of reasoning included: (a) cell metabolic
speciﬁcity related to the Warburg eﬀect, overproduction of
lactate and carbonic acids, and an alteration of membrane
transport as a result of intracellular pH (pHi) regulation;
(b) an unusually high number of proteins implicated in the
transport of chloride; (c) metabolic alterations resulting from
SLC6A8 overexpression and a possibility of increased uptake of
creatine phosphate; (d) a loss of integrin dependent adhesion
FIGURE 1 | Schematic representation of membrane transport-related
proteins corresponding to up-regulated genes from Cluster B in
reference Wilson et al. (2006) and Clusters 7 and 8 in reference
Valk et al. (2004). Plasma membrane, endosomal compartment and a
mitochondrion are shown. Transport directionality is indicated by arrows.
Genes, protein names and transported substrates are shown. Sodium
leak in SLC6 family is indicated using dashed arrows. Blue hexagons
designate glycosylation of AMOG protein. Because physiological
functions of SBP1 and XK remain unclear, these proteins are not
shown in the figure. Notice a high number of proteins transporting
chloride ion and nitrogen-containing substrates. For details see text
and Table 1.
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and AML cell mis-homing triggered by a massive modiﬁcation
of the ion transport within the niche microenvironment.
None of these ideas are mutually exclusive. Because patient
samples were obtained at the time of diagnosis or from
previously untreated individuals, it is safe to assume that no
drug-induced clonal selection contributed to the expression
proﬁles.
“Warburg Effect,” pHi and Membrane
Transport
The last decade has been manifested by an increase in the
number of papers dedicated to the role of energy consumption,
glycolytic metabolism, pH regulation, and ion transport in
cancer. Numerous excellent reviews of the topic exist (Doherty
and Cleveland, 2013; Parks et al., 2013; Reshkin et al., 2014;
Swietach et al., 2014). The general model of the pHi regulation in
cancer is being developed, and it is generally accepted that tumor
cells require a “coordination of multiple proteins” to eﬀectively
regulate pHi in the highly acidic environment of the tumor niche
(Parks et al., 2013). Therefore, only several relevant genes and
proteins whose impact has been well documented previously are
described below.
The up-regulation of GLUT1 transporter, reported in multiple
cancers, is usually attributed to aerobic glycolysis (Warburg
eﬀect; Diaz-Ruiz et al., 2011). The expression of GLUT1 is
under the control of hypoxia-inducible factors (HIFs)-1 and -2,
suggesting a regulatory mechanism directly triggered by hypoxic
conditions created and maintained in rapidly growing tumors
(Chan et al., 2011). The switch to aerobic glycolysis with increased
lactate generation can be also modulated through PI3K/AKT
signaling that contributes to the cell surface expression of
GLUT transporters and activation of multiple glycolytic enzymes
(Doherty and Cleveland, 2013). Thus, GLUT1 without being
directly involved in a regulation of acid-base balance in cancer
cells provides a large inﬂux of glucose that serves as a major
source of lactate. The other metabolic substrate for aerobic
glycolysis is glutamine, which is transported through SLC1A5
(sodium-dependent amino acids transporter, ASCT2; Doherty
and Cleveland, 2013) that has not been up-regulated in the
studied clusters [Cluster B in reference Wilson et al. (2006)
and Clusters 7 and 8 in reference Valk et al. (2004)]. It is
worth noting that SLC16A1 (proton-coupled monocarboxylate
transporter 1) and SLC16A3 (proton-linked monocarboxylate
transporter 4), two transporters implicated in the shuttling of
lactate across the cancer cell plasma membrane, were also not
up-regulated.
The other gene directly implicated in the regulation of pHi is
SLC4A1, an AE1 that mediates the electroneutral Cl(−)/HCO(−)
3 exchange across the plasma membrane. AE1 is an integral
part of a membrane complex involved in HCO(−)3 transport
and regulation termed “transport metabolon.” According to
the model, the co-localization of two major components of
the metabolon, carbonic anhydrase II and AE1 facilitate rapid
carbon dioxide transport across the lipid bilayer (Sterling
et al., 2001). The fact that AE1 is described to form a
macrocomplex (called band 3 macrocomplex) with Rh proteins,
also up-regulated in studied clusters (Table 1), suggests a speciﬁc
functional relationship between these proteins in AML cells
(Bruce et al., 2003; De Rosa et al., 2008). Because the last
complex is envisioned as CO2/O2/NO gas exchange unit, this
may point toward a possible role of nitric oxide in AML
pathogenesis.
Chloride Transport
One surprising feature that can be noticed after Figure 1
examination is a high incidence of channels and transporters
implicated in the transport of chloride ions. A normal serum
concentration of chloride ion is much larger than a cytosolic
concentration. This gradient can be a part of the force driving
an uphill symport of several organic metabolites, such as
amino acids, amino acid-like substrates and creatine or creatine
phosphate (see refs. for SLC6 family above). If genes that are
involved in the membrane transport of a chloride ion are
up-regulated in a poor outcome AML, it might point to the
possibility of a speciﬁc role of chloride ion transport in leukemia.
Several studies describe targeting chloride transport in cancer.
Chloride channels (CLICs speciﬁcally) are implicated in tumor
development. Together with ClC-3, CLICs are perceived as
potential therapeutic targets in solid tumors, see (Peretti et al.,
2014) and references therein. However, additional studies are
needed to better understand the role of chloride channels cancer
pathogenesis.
The other line of research is related to the studies of
small molecules capable of modifying chloride transport.
Prodigiosins, a family of tripyrrolic molecules of natural
origin exhibit anticancer activity. One molecular mechanism
proposed to explain prodigiosin anticancer activity is related
to its ability to stimulate a symport of protons with chloride
ions, and thus, to uncouple proton translocation machinery
(Sato et al., 1998). A synthesis of a series of structurally
diverse prodigiosin analogs revealed that the rate of ion
translocation, rather than anion binding ability, correlates with
the anticancer activity (Sessler et al., 2005). This line of
research resulted in the synthesis of novel compounds capable
of facilitating passive chloride inﬂux followed by sodium entry
via sodium channels, which stimulated formation of reactive
oxygen species, a release of cytochrome c and apoptosis via
caspase activation (Ko et al., 2014). Synthetic chloride ion
transporters (or carriers) that dramatically alter chloride ﬂux
across the cell membrane may represent an interesting option
for targeting cells that signiﬁcantly overexpress chloride ion
transporters.
Nevertheless, the majority of studies of proton dynamics,
lactate metabolism and ion transport were conducted in
model systems representing solid tumors that include colon,
breast, brain, lung, and prostate cancer. The role of transport
mechanisms in leukemia is less studied. Our current data
highlight a possible role of transporters that can be related to
pHi stabilization or chloride ion transport in adult AML. It is
possible that despite a signiﬁcant heterogeneity of AML samples,
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certain subsets can be identiﬁed and used for future diagnostic or
therapeutic application.
Metabolic Alterations and SLC6A8
Overexpression
Another exciting hypothesis that originated from the analysis
of studied clusters is related to the overexpression of SLC6A8,
creatine transporter 1. Recently, Loo et al. (2015) described
a model, where a malignant cell can acquire metabolic
energy thorough the uptake of creatine phosphate. First,
creatine phosphate is synthesized outside of a cancer cell from
creatine and ATP, provided by an adjacent non-malignant cell.
Next, creatine phosphate is taken up by a cancer cell via
SLC6A8. Finally, the high-energy phosphate group from creatine
phosphate is utilized inside of a cancer cell to generate ATP. In
this case, the malignant cell will have no need for the production
of large quantities of “its own” domestically produced ATP. Using
this mechanism metabolic energy can be directly “imported” in
the form of creatine phosphate. Consequently, the major cellular
metabolic pathways can be reprogrammed for the synthesis of
nucleotides and amino acids to sustain rapid cell proliferation.
However, since for every phosphocreatine molecule only
one high energy phosphate is transferred, the process requires
a “shuttle” mechanism, where phosphocreatine enters the
cancer cell through SLC6A8 and after transfer of a high-
energy bond, creatine or creatine metabolites are returned
back to the extracellular space for the next round of creatine
phosphorylation. This proposed mechanism appears to be
diﬀerent from a well described “phosphocreatine shuttle” system,
where a high-energy phosphate, present in ATP, is transferred
intracellularly from mitochondria to the cytosol (Bessman and
Geiger, 1981). Also, rather than being eﬄuxed from a cancer
cell, intracellular creatine is likely metabolized and metabolic
products are removed using transporters located in the plasma
membrane. This might explain an unusual up-regulation of
proteins implicated in the transport of nitrogen containing
compounds and products of nitrogen metabolism (Figure 1).
Membrane Transport and Niche Biology
Another idea is related to the “restraining eﬀect” within
the tumor microenvironment that under normal conditions
suppresses tumor development (Bissell and Hines, 2011). An
interaction between adhesion molecules (beta1-integrin, for
example) expressed on tumor cells, and components of the niche
is envisioned as one of the underlying molecular mechanisms of
this “restraining eﬀect” (Correia and Bissell, 2012). Binding of
ligands to beta1-integrins [and speciﬁcally to very late antigen-
4 (VLA-4, CD49d/CD29), the major integrin responsible for
the homing retention of early hematopoietic progenitors (Rettig
et al., 2012)] is regulated through a series of conformational
changes (Chigaev and Sklar, 2012) which are extremely sensitive
to ionic conditions and the redox microenvironment (Chigaev
et al., 2003, 2004; Liu et al., 2008). Therefore, it is possible that
the overexpression of proteins, implicated in regulation of acid-
base balance and acidiﬁcation of the extracellular milieu, will
dramatically alter adhesive interactions between AML cells and
bone marrow niche components. We envision that the loss of
this critical adhesive interaction will result in a disruption of the
normal niche microenvironment and the creation of an abnormal
cellular ecosystem. The loss of proper cell homing within the
niche can also contribute to altered epigenetic regulation. Radical
modiﬁcation of the bone marrowmicroenvironment by leukemic
cells has been reported previously (Colmone et al., 2008).
Conclusion
Targeting transporters and channels in cancer is presently
envisioned as novel and very promising area of anticancer
therapy (Arcangeli et al., 2009; Oosterwijk and Gillies, 2014).
A successful use of drugs targeting ion channels for treatment of
multiple diseases unrelated to cancer indicates that these drugs
can be well tolerated and safely used over a long time period.
Unfortunately, the majority of current studies of membrane
proteins in cancer are largely limited to solid tumors. Roles of
transport proteins as therapeutic targets and pathogenesis of
leukemia remain largely unexplored.
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